Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Why a Texas congressman believes Chinese biotechs are 'beating us on our ground game'

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Rep. Nathaniel Moran highlights that China is advancing in the early stages of the biotech supply chain, strengthening its control over pharmaceutical innovation and drug licensing deals, prompting US bipartisan legislative efforts to limit Chinese investment and influence in biotech.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a turning point as US law tightens on Chinese biotech investment and supply chains. Assess dependencies on Chinese manufactured ingredients now or risk losing control of your drug innovation pipeline.

◆ Coverage

1 source · 25 Aug 2026

◆ Related on Wire

◆ Topics

Biotechchinabiotechinvestment-restrictionssupply-chaindrug-licensing